PMID- 32598878
OWN - NLM
STAT- MEDLINE
DCOM- 20210621
LR  - 20210621
IS  - 1873-3492 (Electronic)
IS  - 0009-8981 (Linking)
VI  - 509
DP  - 2020 Oct
TI  - Plasma concentration of receptor-interacting protein kinase-3 as a potential 
      biomarker for diagnosis and prognosis in heart failure.
PG  - 273-279
LID - S0009-8981(20)30301-6 [pii]
LID - 10.1016/j.cca.2020.06.039 [doi]
AB  - BACKGROUND: Receptor-interacting serine-threonine kinase 3 (RIP3) is a key 
      mediator of programmed necrosis (necroptosis), and is implicated in cardiac 
      remodeling and heart failure (HF) triggered by ischemia-reperfusion or oxidative 
      stress in animal study. However, its value in the diagnosis and prognosis of 
      human HF remains unclear. METHODS: Plasma RIP3 concentrations in 91 HF patients 
      and 95 healthy volunteers were detected by enzyme-linked immunosorbent assay 
      (ELISA). A receiver operating characteristic (ROC) curve was generated to 
      evaluate the diagnostic value of RIP3. Follow-up was conducted, and the composite 
      endpoint was defined as all-cause mortality/readmission due to decompensated 
      HF/worse New York Heart Association (NYHA) functional class. The relationship 
      between RIP3 and patient outcome was examined. RESULTS: Plasma concentrations of 
      RIP3 were significantly increased in patients with HF compared to controls 
      (P < 0.001). ROC analysis supported plasma RIP3 as a good diagnostic marker for 
      HF, with an optimal cutoff value of 357 pg/ml (AUC = 0.934, sensitivity = 0.846, 
      specificity = 0.905). Kaplan-Meier survival analysis also supported increased 
      plasma RIP3 as a predictor for a poor prognosis in HF (cutoff 
      value = 622.2 pg/ml, P < 0.05). Additionally, binary logistic regression analysis 
      revealed RIP3 to be an independent risk factor for all-cause mortality 
      (OR = 11.844, P = 0.02), worse NYHA (OR = 9.013, P = 0.009) and a composite 
      endpoint (OR = 5.065, P = 0.013). CONCLUSIONS: Plasma concentration of RIP3 is 
      significantly elevated in HF and associated with the prognosis. Plasma RIP3 
      possibly constitutes a valuable diagnostic and prognostic biomarker for HF.
CI  - Copyright (c) 2020 The Author(s). Published by Elsevier B.V. All rights reserved.
FAU - Hu, Xiaomin
AU  - Hu X
AD  - Department of Medical Research Center, Peking Union Medical College Hospital, 
      Chinese Academy of Medical Science & Peking Union Medical College, 100730 
      Beijing, China.
FAU - Li, Hanyu
AU  - Li H
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Science & Peking Union Medical College, 100730 Beijing, China.
FAU - Chen, Xi
AU  - Chen X
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Science & Peking Union Medical College, 100730 Beijing, China.
FAU - Liu, Honghong
AU  - Liu H
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Science & Peking Union Medical College, 100730 Beijing, China.
FAU - Zuo, Wei
AU  - Zuo W
AD  - Department of Pharmacy, Peking Union Medical College Hospital, Chinese Academy of 
      Medical Science & Peking Union Medical College, 100730 Beijing, China.
FAU - Zhang, Yan
AU  - Zhang Y
AD  - Institute of Cardiovascular Sciences, Ministry of Education, Peking University 
      Health Science Center, 100083 Beijing, China; Key Laboratory of Molecular 
      Cardiovascular Sciences, Ministry of Education, Peking University Health Science 
      Center, 100083 Beijing, China.
FAU - Zhang, Shuyang
AU  - Zhang S
AD  - Department of Cardiology, Peking Union Medical College Hospital, Chinese Academy 
      of Medical Science & Peking Union Medical College, 100730 Beijing, China. 
      Electronic address: shuyangzhang103@nrdrs.org.
LA  - eng
PT  - Journal Article
DEP - 20200626
PL  - Netherlands
TA  - Clin Chim Acta
JT  - Clinica chimica acta; international journal of clinical chemistry
JID - 1302422
RN  - 0 (Biomarkers)
SB  - IM
MH  - Animals
MH  - Biomarkers
MH  - *Heart Failure/diagnosis
MH  - Humans
MH  - New York
MH  - Prognosis
MH  - ROC Curve
OTO - NOTNLM
OT  - Diagnosis
OT  - Heart failure
OT  - Necroptosis
OT  - Prognosis
OT  - Receptor-interacting protein kinase-3 (RIP3)
OT  - Risk factor
COIS- Declaration of Competing Interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2020/07/01 06:00
MHDA- 2021/06/22 06:00
CRDT- 2020/06/30 06:00
PHST- 2020/04/08 00:00 [received]
PHST- 2020/06/21 00:00 [revised]
PHST- 2020/06/22 00:00 [accepted]
PHST- 2020/07/01 06:00 [pubmed]
PHST- 2021/06/22 06:00 [medline]
PHST- 2020/06/30 06:00 [entrez]
AID - S0009-8981(20)30301-6 [pii]
AID - 10.1016/j.cca.2020.06.039 [doi]
PST - ppublish
SO  - Clin Chim Acta. 2020 Oct;509:273-279. doi: 10.1016/j.cca.2020.06.039. Epub 2020 
      Jun 26.